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BSTRACT
 
Background
 
The role of gastric acid suppression in
preventing the recurrence of ulcer complications after
the eradication of 
 
Helicobacter pylori
 
 infection in pa-
tients taking long-term low-dose aspirin is uncertain.
 
Methods
 
We enrolled 123 patients who had ulcer
complications after using low-dose aspirin continu-
ously for more than one month and who had 
 
H. pylori
 
infection. After the ulcers had healed and the 
 
H. pylori
 
infection was eradicated, the patients were randomly
assigned to treatment with 30 mg of lansoprazole dai-
ly or placebo, in addition to 100 mg of aspirin daily,
for 12 months. The primary end point was the recur-
rence of ulcer complications.
 
Results
 
During a median follow-up of 12 months,
9 of the 61 patients in the placebo group (14.8 percent),
as compared with 1 of the 62 patients in the lansopra-
zole group (1.6 percent), had a recurrence of ulcer
complications (adjusted hazard ratio, 9.6; 95 percent
confidence interval, 1.2 to 76.1). Of these 10 patients,
4 had evidence of a recurrence of 
 
H. pylori
 
 infection
and 2 had taken nonsteroidal antiinflammatory drugs
before the onset of complications. Patients in the lan-
soprazole group were significantly less likely to have a
recurrence of ulcer complications than patients in
the placebo group (P=0.008). There was no signifi-
cant difference in mortality between the two groups.
 
Conclusions
 
In patients who had ulcer complica-
tions related to the long-term use of low-dose aspirin,
treatment with lansoprazole in addition to the eradi-
cation of 
 
H. pylori
 
 infection significantly reduced the
rate of recurrence of ulcer complications. (N Engl J
Med 2002;346:2033-8.)
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HE efficacy of low-dose aspirin (less than
325 mg daily) in the prevention of cardio-
vascular and cerebrovascular diseases is well
established.
 
1
 
 Patients who are taking low-
dose aspirin, however, have an increased risk of ulcer
complications,
 
2
 
 and some of these patients should be
given prophylactic treatment.
One of the available options for preventing these
ulcer complications is the simultaneous use of proton-
pump inhibitors, which reduce gastric acidity sub-
stantially. In a recent epidemiologic study, the use of
T
 
a proton-pump inhibitor was found to be associated
with a decrease of 80 percent in the risk of gastroin-
testinal bleeding in subjects taking low-dose aspirin.
 
3
 
Use of a proton-pump inhibitor was also shown to
prevent the relapse of endoscopic ulcers in patients re-
ceiving long-term therapy with nonsteroidal antiin-
flammatory drugs (NSAIDs).
 
4,5
 
 Although no random-
ized study has examined the role of proton-pump
inhibitors in subjects taking low-dose aspirin, it seems
likely that the results of these studies of nonaspirin
NSAIDs can be extrapolated to patients who are tak-
ing low-dose aspirin.
Since 
 
Helicobacter pylori
 
 infection is commonly
found in patients with ulcer bleeding and is an im-
portant risk factor for peptic-ulcer bleeding, we com-
pared the efficacy of eradication of 
 
H. pylori 
 
infection
alone with that of the combination of such eradication
with proton-pump inhibitor therapy in preventing the
recurrence of ulcer complications in users of low-
dose aspirin. Because ulcer bleeding occurring early in
the course of aspirin treatment may be related to the
hemorrhagic effect of aspirin on a preexisting ulcer or
to its primary ulcerogenic effect, we limited our study
to patients in whom ulcer bleeding developed after at
least one month of low-dose aspirin therapy.
 
METHODS
 
Study Population
 
This prospective, randomized, controlled trial was conducted at
the Queen Mary Hospital at the University of Hong Kong between
January 1999 and July 2001, in accordance with the principles of
good clinical practice and the Declaration of Helsinki. The study
protocol was approved by the Ethics Committee of the University
of Hong Kong, and all patients gave written informed consent.
We screened for eligibility patients who presented to our en-
doscopy unit with a history of bleeding or gastric-outlet obstruc-
tion due to gastroduodenal ulcer while receiving low-dose aspirin
(defined as a daily dose of less than 325 mg). We enrolled pa-
tients in the study if they met the following criteria: endoscopy
revealed a gastric ulcer, a duodenal ulcer, or a gastroduodenal ulcer,
defined as a break in the mucosa at least 5 mm in diameter with
unequivocal depth; they were receiving low-dose aspirin for at
least one month before complications developed; they had a disease,
such as stroke or ischemic heart disease, that required long-term,
Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
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continuous treatment with low-dose aspirin; they were between 18
and 80 years of age; and the presence of 
 
H. pylori 
 
infection could
be demonstrated by rapid urease testing, histologic analysis of an
antral-biopsy specimen, or both. Patients were excluded if endos-
copy revealed esophagitis; if they had a history of gastric or duo-
denal surgery other than oversewing of a perforation; if they were
allergic to the study drugs; if they were receiving concomitant
treatment with NSAIDs, corticosteroids, or anticoagulant agents;
if they had active cancer; or if the 
 
H. pylori 
 
infection could not
be eradicated after two attempts with eradication therapies.
 
Study Protocol
 
Detection of 
 
H. pylori
 
During endoscopy, two antral-biopsy specimens were obtained
— one from the incisura and the other from the greater curve
within 5 cm of the pylorus. The specimen from the greater curve
was subjected to a standard rapid urease test (Campylobacter-Like
Organism [CLO] test, Delta West). A negative CLO test was de-
fined by the absence of a change in color after 24 hours. The spec-
imen from the incisura was subjected to microscopical examination
for 
 
H. pylori 
 
with the use of hematoxylin and eosin stain and War-
thin–Starry stain, if necessary. Both tests have a sensitivity of 97.5
to 99.4 percent and a specificity of 100 percent in detecting 
 
H. py-
lori.
 
6
 
 
 
H. pylori 
 
was considered to be present if either one of the
two tests was positive; it was considered to be absent or success-
fully eradicated when both tests were negative. The microscopical
detection of 
 
H. pylori 
 
is not affected by the continuous adminis-
tration of a histamine H
 
2
 
 antagonist.
 
7
 
Treatment and Randomization
 
All patients who met the criteria for inclusion and did not meet
the criteria for exclusion received a one-week course of anti-heli-
cobacter therapy consisting of 30 mg of lansoprazole, 1 g of amox-
icillin, and 500 mg of clarithromycin, all given twice daily. This
course was followed by treatment with 20 mg of famotidine given
twice daily for five weeks. Endoscopy was performed again at the
end of treatment to check for healing of the ulcer and eradication
of 
 
H. pylori 
 
infection. Patients in whom endoscopy revealed an un-
healed ulcer were given 20 mg of famotidine twice daily for another
eight weeks. Patients in whom 
 
H. pylori 
 
infection was not eradi-
cated, as indicated by positive results on additional rapid urease tests
or histologic examinations, received a one-week course of triple
therapy consisting of 400 mg of ranitidine bismuth citrate, 1 g of
amoxicillin, and 400 mg of metronidazole, all given twice daily.
Patients with unhealed ulcers and two unsuccessful treatments for
the eradication of 
 
H. pylori 
 
infection were withdrawn from the
study. Patients with healed ulcers in whom 
 
H. pylori 
 
infection had
been eradicated were randomly assigned to receive 100 mg of aspi-
rin and 30 mg of lansoprazole or 100 mg of aspirin and matching
placebo, all given once daily for 12 months. The treatment-group
assignment had been determined previously by a list of random
numbers generated by computer. The investigators who were re-
sponsible for treatment-group assignments and monitoring of the
patients’ progress were unaware of the treatment-group assignments
until the analyses were completed, as were the members of the gas-
trointestinal-events review board.
 
Follow-up
 
Patients were followed as outpatients, with visits every two
months. The administration of an antacid (Gelusil, Parke-Davis) was
permitted for the control of mild symptoms of dyspepsia. Patients
were advised to avoid taking NSAIDs other than the study drug
if possible. Compliance with the regimen was assessed by counts
of the pills that were returned. Upper gastrointestinal tract symp-
toms were assessed at each visit.
Patients were asked to report to the outpatient clinic if they had
persistent ulcer symptoms (epigastric pain, dyspepsia, or recurrent
vomiting) that were not relieved by antacids and to report to the
emergency room if they had evidence of gastrointestinal bleeding
or ulcer complications (melena, hematemesis, or sudden onset of
severe epigastric pain). Endoscopy was then repeated to document
any recurrence of gastroduodenal ulcer. 
 
H. pylori 
 
was detected by
carbon-13 urea breath testing and by additional rapid urease testing
and microscopical examination of gastric mucosal-biopsy specimens.
Blood counts were checked every six months. If the hemoglobin
level had decreased by 2 g per deciliter or more, endoscopy was re-
peated to check for the presence of ulcers, and stool was checked for
the presence of occult blood. No scheduled endoscopy was other-
wise performed.
 
End Points
 
The primary end point was the recurrence of ulcer complica-
tions (bleeding, perforation, or obstruction). The secondary end
point was the recurrence of gastroduodenal ulcer, including ulcer
complications and symptomatic ulcers.
A gastrointestinal-events review board, whose members were
unaware of the patients’ treatment-group assignments, reviewed the
data and determined whether the patients had reached the study
end points according to prespecified criteria (Table 1). Events that
were confirmed and that occurred during treatment or within 14
days after the discontinuation of treatment were included in the
primary analysis. Patients with a recurrence of peptic ulcers were
given standard antiulcer treatment, including histamine H
 
2
 
 an-
tagonists or proton-pump inhibitors for the healing of ulcers, and
were cared for according to the standard practice at the hospi-
tal. Patients who withdrew from the study were followed until
the end of the study for any recurrence of gastrointestinal com-
plications.
 
Statistical Analysis
 
When we began the study, there were no data available about
the rate of relapse of ulcer complications in aspirin users. We es-
timated that at one year, the primary end point (relapse of ulcer
complications) after eradication of 
 
H. pylori 
 
infection would occur
in 20 percent of patients in the placebo group and that the addi-
tion of lansoprazole would reduce the rate of relapse to 5 percent.
It was estimated that we required a minimum of 90 patients in each
treatment group to demonstrate an absolute difference of 15 per-
centage points with a type I error of 0.05 and a type II error of
0.2 (in two-sided tests).
We planned two interim analyses, to be conducted in April
2000 and April 2001. On the basis of the O’Brien–Fleming rules
for early termination, we determined that we would stop the trial
if the difference between the groups in the primary end point
reached a significance level of 0.001 in the first analysis or 0.01
in the second analysis.
 
8
 
 The analyses were performed by independ-
ent investigators who were not involved in the treatment of the
patients studied.
The homogeneity of the treatment groups at base line was ana-
lyzed by the chi-square test with Yates’ correction or Fisher’s exact
test for categorical data and the Mann–Whitney U test for con-
tinuous variables. Statistical analysis of clinical events included the
intention-to-treat population consisting of all patients who were
enrolled in the study and underwent randomization. The proba-
bility of a recurrence of ulcer complications during follow-up was
analyzed with the use of Kaplan–Meier survival estimates. The
log-rank test was used to determine the differences between groups
in the time to a recurrence of ulcer complications. The hazard ra-
tio was adjusted by a Cox proportional-hazards model for the ef-
fects of potential confounding covariates, including the factors
listed in Table 1, on the development of ulcers and ulcer compli-
cations.
SPSS software (SPSS), version 10.0 for Windows was used for
all statistical calculations. All P values are two-sided.
Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
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RESULTS
 
The first interim analysis was performed in April
2000 after 65 patients had been recruited. There were
no recurrences of ulcer complications in the lanso-
prazole group (0 percent), and there were four in
the placebo group (12.1 percent) (P=0.05).
 
9
 
 The
second interim analysis was performed in April 2001,
when 123 patients had been recruited, and because
we found a significant difference between the two
groups (P=0.006) in the occurrence of the primary
end point, we stopped the recruitment and random-
ization of patients. Data analysis was completed in
July 2001, when the median duration of follow-up
was 12 months (range, 3 to 12). The results we re-
port here are based on all 123 randomized patients
with follow-up until July 2001.
 
Characteristics of the Patients
 
Of the 245 patients who underwent endoscopy be-
cause they had peptic-ulcer complications while taking
low-dose aspirin (2 with gastric-outlet obstruction
and 243 with upper gastrointestinal bleeding), 171
were found to be infected with 
 
H. pylori.
 
 Endoscopic
hemostasis was unsuccessful in three patients, and sur-
gery was performed immediately. Forty-one patients
were not enrolled in the study: 28 had used aspirin
for less than a month, 3 were using corticosteroids or
anticoagulant agents in addition to aspirin, 2 had ac-
tive cancer, and 8 declined to participate in the study.
Anti-helicobacter therapy was given to the remain-
ing 127 patients. In four patients, the ulcer did not
heal, 
 
H. pylori 
 
infection was not eradicated despite two
attempts with anti-helicobacter therapy, or both. A
total of 123 patients were randomly assigned to re-
ceive 100 mg of aspirin and either 30 mg of lanso-
prazole or matching placebo, all given once daily. The
two treatment groups were similar with respect to
base-line demographic characteristics, the clinical se-
verity of bleeding (as categorized on the basis of the
vital signs and hemoglobin level on admission, and
the need or lack of need for blood transfusion and en-
doscopic treatment), history or lack of history of pre-
vious ulcer bleeding, the location and size of ulcers,
and the presence or absence of coexisting illnesses
(Table 2).
 
Follow-up
 
The median duration of follow-up was 12 months
in both treatment groups (range, 3 to 12). According
to self-reports, four patients in the lansoprazole group
(6.5 percent) and six patients in the placebo group
(9.8 percent) did not comply with the protocol. In
the lansoprazole group, one patient had an intolerance
of the study medications, one stopped taking aspirin,
and two were lost to follow-up. In the placebo group,
two patients stopped taking aspirin, two were lost to
follow-up, and two used other NSAIDs during the
study. Pill counts indicated that all other patients took
their medication on at least 75 percent of the days
of the study.
 
Recurrence of Gastrointestinal Ulcers and Ulcer 
Complications
 
During the study period, 14 upper gastrointestinal
tract events were adjudicated by the end-points com-
mittee. Of these, 10 events were confirmed.
Four patients had dyspepsia while taking low-dose
aspirin and placebo, but endoscopy did not reveal any
peptic ulcers. In these four patients, dyspepsia subsid-
ed after a short course of antacids, and aspirin therapy
was continued. Two patients were found to have a de-
crease in the hemoglobin level of more than 2 g per
deciliter from the base-line level after the ulcer had
healed; in both these patients, stool was positive for
occult blood. Endoscopy showed the presence of a
gastric ulcer in one patient and a duodenal ulcer in
the other patient. Eight patients presented with clin-
ical evidence of upper gastrointestinal tract bleeding.
Gastric ulcers were detected by endoscopy in all of
these patients. One patient in the lansoprazole group
died during the study period because of aspiration
pneumonia secondary to a recurrence of stroke.
One episode of gastrointestinal bleeding occurred
in the lansoprazole group and nine events occurred in
the placebo group. The estimated probability of re-
currence of gastroduodenal ulcers and ulcer compli-
cations was 1.6 percent in the lansoprazole group (1 of
62; 95 percent confidence interval, 0 to 9 percent)
and 14.8 percent in the placebo group (9 of 61; 95
percent confidence interval, 7 to 26 percent; P=
0.008; hazard ratio, 10.6; 95 percent confidence in-
terval, 1.3 to 86.1). The log-rank test showed a sig-
nificant difference between the two groups in the time
to recurrence (P=0.008). After adjustment for the
 
T
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 1.
 
 P
 
RESPECIFIED
 
 C
 
RITERIA
 
 
 
FOR
 
 U
 
LCER
 
 C
 
OMPLICATIONS
 
.
 
T
 
YPE
 
 
 
OF
 
 E
 
VENT
 
C
 
ONFIRMATORY
 
 C
 
RITERIA
 
Upper gastrointestinal
tract bleeding
Hematemesis, melena, or both, with a nonmalig-
nant ulcer found on endoscopy or at surgery; 
decrease of »2 g per deciliter in the hemo-
globin level with a nonmalignant ulcer found 
on endoscopy and occult-blood–positive stool
Gastric-outlet 
obstruction
Nausea and vomiting «24 hr after eating, with 
stenosis in the distal part of the stomach or 
duodenum, as a result of a nonmalignant 
ulcer found on endoscopy or at surgery
Gastric or duodenal
perforation
Presence of perforation due to a nonmalignant 
ulcer that requires surgery
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possible confounding covariates, including age, his-
tory or lack of history of ulcer, history or lack of his-
tory of bleeding, location of ulcers, size of ulcers,
and the presence or absence of coexisting illness, the
hazard ratio according to the Cox proportional-haz-
ards model was 9.6 (95 percent confidence interval,
1.2 to 76.1).
The characteristics of the patients who had recur-
rent gastroduodenal-ulcer complications are shown
in Table 3. Two patients in the placebo group re-
quired endoscopic treatment to stop the bleeding.
Of the 10 patients who had gastrointestinal events
during the study, 4 (all in the placebo group) had a
relapse of 
 
H. pylori 
 
infection, as determined by car-
bon-13 urea breath testing, rapid urease testing, and
histologic examination of an antral-biopsy specimen.
Two patients had taken NSAIDs within four weeks
before the onset of ulcer complications.
 
DISCUSSION
 
This study demonstrates that in patients who had
been infected with 
 
H. pylori 
 
and had gastrointestinal
bleeding while taking low-dose aspirin, maintenance
treatment with a proton-pump inhibitor and eradi-
cation of the 
 
H. pylori 
 
infection led to a significant
reduction in the recurrence of ulcer complications as
compared with the eradication of 
 
H. pylori 
 
infection
alone.
Since the dose of aspirin used in the primary and
secondary prevention of vascular diseases is much low-
er than the doses of conventional nonaspirin NSAIDs
used in treating patients with osteoarthritis or rheu-
 
*Plus–minus values are means ±SD.
†Shock was defined as a systolic blood pressure of less than 100 mm Hg with a pulse of 100 beats
per minute or more.
 
T
 
ABLE
 
 2.
 
 B
 
ASE
 
-L
 
INE
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 P
 
ATIENTS
 
.*
 
V
 
ARIABLE
 
L
 
ANSOPRAZOLE
 
 G
 
ROUP
 
(N=62)
P
 
LACEBO
 
 G
 
ROUP
 
(N=61)
 
Continuous variables
 
Age — yr 71.5±8.0 69.1±7.6
Duration of follow-up — mo
Median 12 12
Range 3–12 3–12
Hemoglobin level on admission — g/dl 9.9±1.5 10.2±1.8
Transfusion required — units 1.03±1.16 0.97±1.21
Size of ulcer — mm 11.6±4.6 11.2±4.0
Categorical variables
Female sex — no. (%) 16 (25.8) 19 (31.1)
Age »65 yr — no. (%) 48 (77.4) 43 (70.5)
Smoking — no. (%) 8 (12.9) 12 (19.7)
Alcohol use — no. (%) 9 (14.5) 10 (16.4)
Medical history — no. (%)
Cerebrovascular accident 28 (45.2) 36 (59.0)
Ischemic heart disease 34 (54.8) 25 (41.0)
Other concomitant illness 11 (17.7) 15 (24.6)
History of ulcer 6 (9.7) 7 (11.5)
History of bleeding 4 (6.5) 3 (4.9)
Clinical and laboratory variables
Pulse »100 beats/min on admission — no. (%) 11 (17.7) 7 (11.5)
Systolic blood pressure <100 mm Hg on admission 
— no. (%)
9 (14.5) 7 (11.5)
Shock at presentation — no. (%)† 8 (12.9) 6 (9.8)
Serum urea level >10 mmol/liter — no. (%) 43 (69.4) 46 (75.4)
Transfusion required — no. (%)
None 22 (35.5) 28 (45.9)
1–2 units 32 (51.6) 25 (41.0)
3–4 units 6 (9.7) 7 (11.5)
>4 units 2 (3.2) 1 (1.6)
Location of ulcer — no. (%)
Gastric 47 (75.8) 44 (72.1)
Duodenal 12 (19.4) 14 (23.0)
Gastroduodenal 3 (4.8) 3 (4.9)
Ulcer size >10 mm — no. (%) 27 (43.5) 34 (55.7)
Endoscopic hemostasis required — no. (%) 20 (32.3) 16 (26.2)
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matoid arthritis, the risk of complications associated
with low-dose aspirin might be expected to be corre-
spondingly lower than the risk associated with those
treatments.10 However, the effects of proton-pump
inhibitor treatment in this aspirin-treated population
had not been known.
Our study population was uniform in that all pa-
tients had had H. pylori infection that was success-
fully treated before randomization. We did not study
the effect of previous H. pylori infection on the risk
of a recurrence of ulcer complications in patients tak-
ing low-dose aspirin. Nevertheless, in our study, 14.8
percent of the patients in the placebo group had re-
currences of ulcer complications despite the initial
eradication of H. pylori infection. This high rate of
recurrence may be attributable in part to the presence
of other risk factors for a relapse of ulcer, including
the recurrence of H. pylori infection in four patients
and the concomitant use of NSAIDs in two patients.
Even if we exclude these 6 patients from the analysis,
however, 5 percent of the other patients in the pla-
cebo group (3 of 55) had a recurrence of ulcer com-
plications despite the absence of other potential risk
factors for a relapse of ulcer. This finding implies that
the ulcerogenic effect of low-dose aspirin cannot be
completely abolished by the eradication of H. pylori
infection alone. The persistent ulcerogenic effect of
aspirin is probably related to the fact that, even at a
very low dose, aspirin can inhibit the synthesis of a
substantial proportion of protective gastric prosta-
glandins.11
We found that the addition of the proton-pump
inhibitor lansoprazole significantly reduced the rate
of recurrence of ulcer complications. Our findings
confirm those of an epidemiologic study that showed
a reduced risk of ulcer bleeding in patients taking low-
dose aspirin and a proton-pump inhibitor at the same
time.3 The reduction in the recurrence of aspirin-relat-
ed ulcer bleeding that occurs as a result of the acid
suppression associated with proton-pump inhibitors
is most likely related to the protective effect of these
drugs against mucosal injury. Another possible mech-
*Plus–minus values are means ±SD.
†Two patients are not included, because their rebleeding was identified only by a decrease in
hemoglobin levels.
‡Shock was defined as a systolic blood pressure of less than 100 mm Hg with a pulse of 100 beats
per minute or more.
TABLE 3. CHARACTERISTICS OF PATIENTS WITH RECURRENCES 
OF ULCER COMPLICATIONS OR CLINICAL REBLEEDING.*
VARIABLE
LANSOPRAZOLE
GROUP
(N=62)
PLACEBO GROUP
(N=61)
Patients with recurrences of complications
Total — no. (%) 1 (1.6) 9 (14.8)
Site of relapse — no.
Gastric ulcer
Duodenal ulcer
1
0
8
1
Time to relapse — no.
<6 mo
»6 mo
0
1
2
7
Recurrence of H. pylori infection — no. 0 4
Deaths — no. 1 0
Patients with clinical rebleeding†
Total — no. 0 8
Age — yr — 66.5±8.5
Female sex — no. (%) — 4 (50.0)
Transfusion required — units
Range
— 1.13±1.46
0–4
Location of ulcer — no.
Gastric
Duodenal
—
—
8
0
Range of ulcer size — mm — 5–15
Hemoglobin level on admission — g/dl — 10.34±2.09
Pulse »100 beats/min on admission — no. (%) — 3 (37.5)
Systolic blood pressure <100 mm Hg on admission — no. (%) — 2 (25.0)
Shock at presentation — no. (%)‡ — 2 (25.0)
Serum urea level >10 mmol/liter — no. (%) — 5 (62.5)
Endoscopic hemostasis required — no. (%) — 2 (25.0)
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anism is that through acid suppression, the proton-
pump inhibitor reduces acute aspirin-induced micro-
bleeding from erosions.12
Our study had several drawbacks. We did not in-
clude a control group in which H. pylori infection
was not eradicated, which would have enabled us to
identify more definitively the effects of H. pylori in-
fection in users of low-dose aspirin. Our local ethics
committee thought it would be unethical to resume
aspirin therapy without adding any other treatment
in patients with H. pylori-infected ulcers, especially
in those with complications such as bleeding. More-
over, there is a consensus that H. pylori infection in
bleeding ulcers should be eradicated.13 Second, al-
though we showed that lansoprazole reduced the rate
of relapse of ulcer complications significantly better
than placebo, with a hazard ratio of 9.6, the 95 per-
cent confidence interval around the ratio was wide,
suggesting that one must be cautious when translat-
ing our findings into practice. The wide confidence
interval is probably related to the low rate of events in
the lansoprazole group. In conclusion, we have dem-
onstrated that after the initial eradication of H. pylori
infection, proton-pump inhibitor therapy significantly
reduces the risk of recurrences of ulcer complications
in patients who continue to take low-dose aspirin.
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